Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters

被引:25
作者
Colabufo, Nicola A. [1 ]
Contino, Marialessandra [1 ]
Cantore, Mariangela [1 ,2 ]
Capparelli, Elena [1 ]
Perrone, Maria Grazia [1 ]
Cassano, Giuseppe [3 ]
Gasparre, Giuseppe [3 ]
Leopoldo, Marcello [1 ]
Berardi, Francesco [1 ]
Perrone, Roberto [1 ]
机构
[1] Univ Bari ALDO MORO, Dipartimento Farm, I-70125 Bari, Italy
[2] Natl Canc Inst, Clin Expt Oncol Lab, I-70124 Bari, Italy
[3] Univ Bari ALDO MORO, Univ Bari, Dipartimento Biosci Biotecnol & Sci Farmacol, I-70125 Bari, Italy
关键词
P-glycoprotein; Naphthalenyl derivatives; BCRP; MRP1; MDR revertant agents; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CANCER; INHIBITORS; MRP1; BCRP; RADIOTRACER; MODULATION; DESIGN; ASSAYS;
D O I
10.1016/j.bmc.2012.12.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Substituted naphthalenyl derivatives bearing oxazole, or thiazole or furyl heteronuclei have been carried out as bioisosters of aryl-oxazoles and -thiazoles derivatives previously reported in order to investigate the role of the hindrance on the activity towards P-gp/BCRP/and MRP1 transporters. In addition, the role of naphthalenyl group to modulate P-gp intrinsic activity of these compounds was ascertained. The results demonstrated that all naphthalenyl derivatives displayed comparable P-gp activity with respect to lead compounds previously characterized in our SAR studies but were less active towards BCRP and MRP1 pumps. In terms of intrinsic activity, the replacement of aryl with naphthalenyl moiety led to P-gp inhibitors, unambiguous or ambiguous substrates on the base of the heteronucleus and the substituent on the naphthalenyl fragment. Indeed, oxazole derivatives were: inhibitors (R = H, F, OH), unambiguous substrates (R = OCH3), or ambiguous substrate (R = Br); thiazole derivatives were: unambiguous substrates (R = OCH3, Br), or ambiguous substrates (R = H, F). Finally furyl derivatives were ambiguous substrates. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1324 / 1332
页数:9
相关论文
共 29 条
[1]  
ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145
[2]   Inhibitors of multidrug resistance to antitumor agents (MDR) [J].
Avendaño, C ;
Menéndez, JC .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (02) :159-193
[3]   Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor [J].
Bauer, Florian ;
Kuntner, Claudia ;
Bankstahl, Jens P. ;
Wanek, Thomas ;
Bankstahl, Marion ;
Stanek, Johann ;
Mairinger, Severin ;
Doerner, Bernd ;
Loescher, Wolfgang ;
Mueller, Markus ;
Erker, Thomas ;
Langer, Oliver .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (15) :5489-5497
[4]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[5]   Multi-Drug-Resistance-Reverting Agents: 2-Aryloxazole and 2-Arylthiazole Derivatives as Potent BCRP or MRP1 Inhibitors [J].
Colabufo, Nicola A. ;
Berardi, Francesco ;
Perrone, Maria Grazia ;
Cantore, Mariangela ;
Contino, Marialessandra ;
Inglese, Carmela ;
Niso, Mauro ;
Perrone, Roberto .
CHEMMEDCHEM, 2009, 4 (02) :188-195
[6]   Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives [J].
Colabufo, Nicola Antonio ;
Berardi, Francesco ;
Cantore, Mariangela ;
Perrone, Maria Grazia ;
Contino, Marialessandra ;
Inglese, Carmela ;
Niso, Mauro ;
Perrone, Roberto ;
Azzariti, Amalia ;
Simone, Grazia Maria ;
Porcelli, Letizia ;
Paradiso, Angelo .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (01) :362-373
[7]  
Colabufo NA, 2010, CURR TOP MED CHEM, V10, P1701
[8]   Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood-Brain Barrier [J].
Doerner, Bernd ;
Kuntner, Claudia ;
Bankstahl, Jens P. ;
Bankstahl, Marion ;
Stanek, Johann ;
Wanek, Thomas ;
Stundner, Gloria ;
Mairinger, Severin ;
Loescher, Wolfgang ;
Mueller, Markus ;
Langer, Oliver ;
Erker, Thomas .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (19) :6073-6082
[9]   Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) [J].
Doyle, LA ;
Ross, DD .
ONCOGENE, 2003, 22 (47) :7340-7358
[10]  
EIDELMAN O, 1989, METHOD ENZYMOL, V172, P122